{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:21:45Z","timestamp":1747207305203,"version":"3.40.5"},"reference-count":138,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2023,8,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respirato-ry syndrome Coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and threatens public health and safety. Nowadays, modern society has faced a new challenging problem, the emergence of novel SARS-CoV-2 variants of concern (VOCs). In this context, the Omicron (B.1.1.529) vari-ant, having more than 60 mutations when compared to its ancestral wild-type virus, has infected many individuals around the world. It is rapidly spread person-to-person due to its increased trans-missibility. Additionally, it was demonstrated that this newest variant and its subvariants have the capability of evading the host immune system, being resistant to neutralizing antibodies. Moreover, it has been proven to be resistant to monoclonal antibodies and several different vaccines. This abil-ity is associated with a huge number of mutations associated with its spike (S) glycoprotein, which presents at least 15 mutations. These mutations are able to modify the way how this virus interacts with the host angiotensin-converting enzyme 2 (ACE2), increasing its infectivity and making the therapeutic alternatives more ineffective. Concerning its chymotrypsin-like picornavirus 3C-like protease (3CLpro) and RNA-dependent RNA polymerase (RdRp), it has been seen that some com-pounds can be active against different SARS-CoV-2 variants, in a similar mode than its wild-type precursor. This broad spectrum of action for some drugs could be attributed to the fact that the cur-rently identified mutations found in 3CLpro and RNA proteins being localized near the catalytic binding site, conserving their activities. Herein this review, we provide a great and unprecedented compilation of all identified and\/or repurposed compounds\/drugs against this threatening variant, Omicron. The main targets for those compounds are the protein-protein interface (PPI) of S protein with ACE2, 3CLpro, RdRp, and Nucleocapsid (N) protein. Some of these studies have presented on-ly in silico data, having a lack of experimental results to prove their findings. However, these should be considered here since other research teams can use their observations to design and investigate new potential agents. Finally, we believe that our review will contribute to several studies that are in progress worldwide, compiling several interesting aspects about VOCs associated with SARS-CoV-2, as well as describing the results for different chemical classes of compounds that could be prom-ising as prototypes for designing new and more effective antiviral agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026623666230411095417","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T03:58:11Z","timestamp":1681444691000},"page":"1625-1639","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research"],"prefix":"10.2174","volume":"23","author":[{"given":"Weslany","family":"Souza Rocha","sequence":"first","affiliation":[{"name":"Research Group on Biological and Molecular Chemistry, Institute of Chemistry and Biotechnology, Federal University of Alagoas, Macei\u00f3, 57072-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-6026","authenticated-orcid":true,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Ji'nan, 250012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1527-4501","authenticated-orcid":true,"given":"Edeildo","family":"Ferreira da Silva-J\u00fanior","sequence":"additional","affiliation":[{"name":"Research Group on Biological and Molecular Chemistry, Institute of Chemistry and Biotechnology, Federal University\nof Alagoas, Macei\u00f3, 57072-970, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.cell.2020.11.020","volume":"184","author":"Volz E.","year":"2021","unstructured":"Volz E.; Hill V.; McCrone J.T.; Price A.; Jorgensen D.; O\u2019Toole \u00c1.; Southgate J.; Johnson R.; Jackson B.; Nascimento F.F.; Rey S.M.; Nicholls S.M.; Colquhoun R.M.; da Silva Filipe A.; Shepherd J.; Pascall D.J.; Shah R.; Jesudason N.; Li K.; Jarrett R.; Pacchiarini N.; Bull M.; Geidelberg L.; Siveroni I.; Goodfellow I.; Loman N.J.; Pybus O.G.; Robertson D.L.; Thomson E.C.; Rambaut A.; Connor T.R.; Koshy C.; Wise E.; Cortes N.; Lynch J.; Kidd S.; Mori M.; Fairley D.J.; Curran T.; McKenna J.P.; Adams H.; Fraser C.; Golubchik T.; Bonsall D.; Moore C.; Caddy S.L.; Khokhar F.A.; Wantoch M.; Reynolds N.; Warne B.; Maksimovic J.; Spellman K.; McCluggage K.; John M.; Beer R.; Afifi S.; Morgan S.; Marchbank A.; Price A.; Kitchen C.; Gulliver H.; Merrick I.; Southgate J.; Guest M.; Munn R.; Workman T.; Connor T.R.; Fuller W.; Bresner C.; Snell L.B.; Charalampous T.; Nebbia G.; Batra R.; Edgeworth J.; Robson S.C.; Beckett A.; Loveson K.F.; Aanensen D.M.; Underwood A.P.; Yeats C.A.; Abudahab K.; Taylor B.E.W.; Menegazzo M.; Clark G.; Smith W.; Khakh M.; Fleming V.M.; Lister M.M.; Howson-Wells H.C.; Berry L.; Boswell T.; Joseph A.; Willingham I.; Bird P.; Helmer T.; Fallon K.; Holmes C.; Tang J.; Raviprakash V.; Campbell S.; Sheriff N.; Loose M.W.; Holmes N.; Moore C.; Carlile M.; Wright V.; Sang F.; Debebe J.; Coll F.; Signell A.W.; Betancor G.; Wilson H.D.; Feltwell T.; Houldcroft C.J.; Eldirdiri S.; Kenyon A.; Davis T.; Pybus O.; du Plessis L.; Zarebski A.; Raghwani J.; Kraemer M.; Francois S.; Attwood S.; Vasylyeva T.; Torok M.E.; Hamilton W.L.; Goodfellow I.G.; Hall G.; Jahun A.S.; Chaudhry Y.; Hosmillo M.; Pinckert M.L.; Georgana I.; Yakovleva A.; Meredith L.W.; Moses S.; Lowe H.; Ryan F.; Fisher C.L.; Awan A.R.; Boyes J.; Breuer J.; Harris K.A.; Brown J.R.; Shah D.; Atkinson L.; Lee J.C.D.; Alcolea-Medina A.; Moore N.; Cortes N.; Williams R.; Chapman M.R.; Levett L.J.; Heaney J.; Smith D.L.; Bashton M.; Young G.R.; Allan J.; Loh J.; Randell P.A.; Cox A.; Madona P.; Holmes A.; Bolt F.; Price J.; Mookerjee S.; Rowan A.; Taylor G.P.; Ragonnet-Cronin M.; Nascimento F.F.; Jorgensen D.; Siveroni I.; Johnson R.; Boyd O.; Geidelberg L.; Volz E.M.; Brunker K.; Smollett K.L.; Loman N.J.; Quick J.; McMurray C.; Stockton J.; Nicholls S.; Rowe W.; Poplawski R.; Martinez-Nunez R.T.; Mason J.; Robinson T.I.; O\u2019Toole E.; Watts J.; Breen C.; Cowell A.; Ludden C.; Sluga G.; Machin N.W.; Ahmad S.S.Y.; George R.P.; Halstead F.; Sivaprakasam V.; Thomson E.C.; Shepherd J.G.; Asamaphan P.; Niebel M.O.; Li K.K.; Shah R.N.; Jesudason N.G.; Parr Y.A.; Tong L.; Broos A.; Mair D.; Nichols J.; Carmichael S.N.; Nomikou K.; Aranday-Cortes E.; Johnson N.; Starinskij I.; da Silva Filipe A.; Robertson D.L.; Orton R.J.; Hughes J.; Vattipally S.; Singer J.B.; Hale A.D.; Macfarlane-Smith L.R.; Harper K.L.; Taha Y.; Payne B.A.I.; Burton-Fanning S.; Waugh S.; Collins J.; Eltringham G.; Templeton K.E.; McHugh M.P.; Dewar R.; Wastenge E.; Dervisevic S.; Stanley R.; Prakash R.; Stuart C.; Elumogo N.; Sethi D.K.; Meader E.J.; Coupland L.J.; Potter W.; Graham C.; Barton E.; Padgett D.; Scott G.; Swindells E.; Greenaway J.; Nelson A.; Yew W.C.; Resende Silva P.C.; Andersson M.; Shaw R.; Peto T.; Justice A.; Eyre D.; Crooke D.; Hoosdally S.; Sloan T.J.; Duckworth N.; Walsh S.; Chauhan A.J.; Glaysher S.; Bicknell K.; Wyllie S.; Butcher E.; Elliott S.; Lloyd A.; Impey R.; Levene N.; Monaghan L.; Bradley D.T.; Allara E.; Pearson C.; Muir P.; Vipond I.B.; Hopes R.; Pymont H.M.; Hutchings S.; Curran M.D.; Parmar S.; Lackenby A.; Mbisa T.; Platt S.; Miah S.; Bibby D.; Manso C.; Hubb J.; Chand M.; Dabrera G.; Ramsay M.; Bradshaw D.; Thornton A.; Myers R.; Schaefer U.; Groves N.; Gallagher E.; Lee D.; Williams D.; Ellaby N.; Harrison I.; Hartman H.; Manesis N.; Patel V.; Bishop C.; Chalker V.; Osman H.; Bosworth A.; Robinson E.; Holden M.T.G.; Shaaban S.; Birchley A.; Adams A.; Davies A.; Gaskin A.; Plimmer A.; Gatica-Wilcox B.; McKerr C.; Moore C.; Williams C.; Heyburn D.; De Lacy E.; Hilvers E.; Downing F.; Shankar G.; Jones H.; Asad H.; Coombes J.; Watkins J.; Evans J.M.; Fina L.; Gifford L.; Gilbert L.; Graham L.; Perry M.; Morgan M.; Bull M.; Cronin M.; Pacchiarini N.; Craine N.; Jones R.; Howe R.; Corden S.; Rey S.; Kumziene-Summerhayes S.; Taylor S.; Cottrell S.; Jones S.; Edwards S.; O\u2019Grady J.; Page A.J.; Wain J.; Webber M.A.; Mather A.E.; Baker D.J.; Rudder S.; Yasir M.; Thomson N.M.; Aydin A.; Tedim A.P.; Kay G.L.; Trotter A.J.; Gilroy R.A.J.; Alikhan N.F.; de Oliveira Martins L.; Le-Viet T.; Meadows L.; Kolyva A.; Diaz M.; Bell A.; Gutierrez A.V.; Charles I.G.; Adriaenssens E.M.; Kingsley R.A.; Casey A.; Simpson D.A.; Molnar Z.; Thompson T.; Acheson E.; Masoli J.A.H.; Knight B.A.; Hattersley A.; Ellard S.; Auckland C.; Mahungu T.W.; Irish-Tavares D.; Haque T.; Bourgeois Y.; Scarlett G.P.; Partridge D.G.; Raza M.; Evans C.; Johnson K.; Liggett S.; Baker P.; Essex S.; Lyons R.A.; Caller L.G.; Castellano S.; Williams R.J.; Kristiansen M.; Roy S.; Williams C.A.; Dyal P.L.; Tutill H.J.; Panchbhaya Y.N.; Forrest L.M.; Niola P.; Findlay J.; Brooks T.T.; Gavriil A.; Mestek-Boukhibar L.; Weeks S.; Pandey S.; Berry L.; Jones K.; Richter A.; Beggs A.; Smith C.P.; Bucca G.; Hesketh A.R.; Harrison E.M.; Peacock S.J.; Palmer S.; Churcher C.M.; Bellis K.L.; Girgis S.T.; Naydenova P.; Blane B.; Sridhar S.; Ruis C.; Forrest S.; Cormie C.; Gill H.K.; Dias J.; Higginson E.E.; Maes M.; Young J.; Kermack L.M.; Hadjirin N.F.; Aggarwal D.; Griffith L.; Swingler T.; Davidson R.K.; Rambaut A.; Williams T.; Balcazar C.E.; Gallagher M.D.; O\u2019Toole \u00c1.; Rooke S.; Jackson B.; Colquhoun R.; Ashworth J.; Hill V.; McCrone J.T.; Scher E.; Yu X.; Williamson K.A.; Stanton T.D.; Michell S.L.; Bewshea C.M.; Temperton B.; Michelsen M.L.; Warwick-Dugdale J.; Manley R.; Farbos A.; Harrison J.W.; Sambles C.M.; Studholme D.J.; Jeffries A.R.; Darby A.C.; Hiscox J.A.; Paterson S.; Iturriza-Gomara M.; Jackson K.A.; Lucaci A.O.; Vamos E.E.; Hughes M.; Rainbow L.; Eccles R.; Nelson C.; Whitehead M.; Turtle L.; Haldenby S.T.; Gregory R.; Gemmell M.; Kwiatkowski D.; de Silva T.I.; Smith N.; Angyal A.; Lindsey B.B.; Groves D.C.; Green L.R.; Wang D.; Freeman T.M.; Parker M.D.; Keeley A.J.; Parsons P.J.; Tucker R.M.; Brown R.; Wyles M.; Constantinidou C.; Unnikrishnan M.; Ott S.; Cheng J.K.J.; Bridgewater H.E.; Frost L.R.; Taylor-Joyce G.; Stark R.; Baxter L.; Alam M.T.; Brown P.E.; McClure P.C.; Chappell J.G.; Tsoleridis T.; Ball J.; Grammatopoulos D.; Buck D.; Todd J.A.; Green A.; Trebes A.; MacIntyre-Cockett G.; de Cesare M.; Langford C.; Alderton A.; Amato R.; Goncalves S.; Jackson D.K.; Johnston I.; Sillitoe J.; Palmer S.; Lawniczak M.; Berriman M.; Danesh J.; Livett R.; Shirley L.; Farr B.; Quail M.; Thurston S.; Park N.; Betteridge E.; Weldon D.; Goodwin S.; Nelson R.; Beaver C.; Letchford L.; Jackson D.A.; Foulser L.; McMinn L.; Prestwood L.; Kay S.; Kane L.; Dorman M.J.; Martincorena I.; Puethe C.; Keatley J.P.; Tonkin-Hill G.; Smith C.; Jamrozy D.; Beale M.A.; Patel M.; Ariani C.; Spencer-Chapman M.; Drury E.; Lo S.; Rajatileka S.; Scott C.; James K.; Buddenborg S.K.; Berger D.J.; Patel G.; Garcia-Casado M.V.; Dibling T.; McGuigan S.; Rogers H.A.; Hunter A.D.; Souster E.; Neaverson A.S.; Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell 2021,184(1),64-75.e11","journal-title":"Cell"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bsheal.2022.04.004","volume":"4","author":"Weng S.","year":"2022","unstructured":"Weng S.; Shang J.; Cheng Y.; Zhou H.; Ji C.; Yang R.; Wu A.; Genetic differentiation and diversity of SARS-CoV-2 Omicron variant in its early outbreak. Biosafety Health 2022,4(3),171-178","journal-title":"Biosafety Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jobb.2021.12.001","volume":"4","author":"Sun Y.","year":"2022","unstructured":"Sun Y.; Lin W.; Dong W.; Xu J.; Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant. J Biosafety Biosec 2022,4(1),33-37","journal-title":"J Biosafety Biosec"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"Viana R.","year":"2022","unstructured":"Viana R.; Moyo S.; Amoako D.G.; Tegally H.; Scheepers C.; Althaus C.L.; Anyaneji U.J.; Bester P.A.; Boni M.F.; Chand M.; Choga W.T.; Colquhoun R.; Davids M.; Deforche K.; Doolabh D.; du Plessis L.; Engelbrecht S.; Everatt J.; Giandhari J.; Giovanetti M.; Hardie D.; Hill V.; Hsiao N.Y.; Iranzadeh A.; Ismail A.; Joseph C.; Joseph R.; Koopile L.; Kosakovsky Pond S.L.; Kraemer M.U.G.; Kuate-Lere L.; Laguda-Akingba O.; Lesetedi-Mafoko O.; Lessells R.J.; Lockman S.; Lucaci A.G.; Maharaj A.; Mahlangu B.; Maponga T.; Mahlakwane K.; Makatini Z.; Marais G.; Maruapula D.; Masupu K.; Matshaba M.; Mayaphi S.; Mbhele N.; Mbulawa M.B.; Mendes A.; Mlisana K.; Mnguni A.; Mohale T.; Moir M.; Moruisi K.; Mosepele M.; Motsatsi G.; Motswaledi M.S.; Mphoyakgosi T.; Msomi N.; Mwangi P.N.; Naidoo Y.; Ntuli N.; Nyaga M.; Olubayo L.; Pillay S.; Radibe B.; Ramphal Y.; Ramphal U.; San J.E.; Scott L.; Shapiro R.; Singh L.; Smith-Lawrence P.; Stevens W.; Strydom A.; Subramoney K.; Tebeila N.; Tshiabuila D.; Tsui J.; van Wyk S.; Weaver S.; Wibmer C.K.; Wilkinson E.; Wolter N.; Zarebski A.E.; Zuze B.; Goedhals D.; Preiser W.; Treurnicht F.; Venter M.; Williamson C.; Pybus O.G.; Bhiman J.; Glass A.; Martin D.P.; Rambaut A.; Gaseitsiwe S.; von Gottberg A.; de Oliveira T.; Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022,603(7902),679-686","journal-title":"Nature"},{"key":"ref=5","unstructured":"Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. WHOAvailable From:  [Accessed on Jul 6, 2022]."},{"key":"ref=6","unstructured":"WHO Coronavirus (COVID-19) Dashboard. WHOAvailable From:"},{"key":"ref=7","unstructured":"Omicron variant: What you need to know. CDCAvailable From:  [Accessed on Jul 12, 2022]."},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"830527","DOI":"10.3389\/fimmu.2021.830527","volume":"12","author":"Shah M.","year":"2022","unstructured":"Shah M.; Woo H.G.; Omicron: A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front Immunol 2022,12,830527","journal-title":"Front Immunol"},{"journal-title":"Tracking of variants","key":"ref=9","unstructured":"Tracking of variants GISAIDAvailable From:  [Accessed on Jul 7, 2022]."},{"key":"ref=10","unstructured":"Tracking SARS-CoV-2 variants. WHOAvailable From:  [Accessed on Jul 6, 2022]."},{"key":"ref=11","unstructured":"Science Brief: Omicron (B.1.1.529) Variant. CDCAvailable From:  [Accessed on Jul 6, 2022]."},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.molcel.2022.03.028","volume":"82","author":"Gobeil S.M.C.","year":"2022","unstructured":"Gobeil S.M.C.; Henderson R.; Stalls V.; Janowska K.; Huang X.; May A.; Speakman M.; Beaudoin E.; Manne K.; Li D.; Parks R.; Barr M.; Deyton M.; Martin M.; Mansouri K.; Edwards R.J.; Eaton A.; Montefiori D.C.; Sempowski G.D.; Saunders K.O.; Wiehe K.; Williams W.; Korber B.; Haynes B.F.; Acharya P.; Structural diversity of the SARS-CoV-2 Omicron spike. Mol Cell 2022,82(11),2050-2068.e6","journal-title":"Mol Cell"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"100206","DOI":"10.1016\/j.xinn.2022.100206","volume":"3","author":"Du P.","year":"2022","unstructured":"Du P.; Gao G.F.; Wang Q.; The mysterious origins of the Omicron variant of SARS-CoV-2. Innovation 2022,3(2),100206","journal-title":"Innovation"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"110924","DOI":"10.1016\/j.celrep.2022.110924","volume":"39","author":"Wang Q.","year":"2022","unstructured":"Wang Q.; Anang S.; Iketani S.; Guo Y.; Liu L.; Katsamba P.S.; Shapiro L.; Ho D.D.; Sodroski J.G.; Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Rep 2022,39(11),110924","journal-title":"Cell Rep"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/acs.jcim.1c01451","volume":"62","author":"Chen J.","year":"2022","unstructured":"Chen J.; Wang R.; Gilby N.B.; Wei G.W.; omicron variant (b.1.1.529): infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model 2022,62(2),412-422","journal-title":"J Chem Inf Model"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1021\/acs.jcim.1c01243","volume":"62","author":"Fratev F.","year":"2022","unstructured":"Fratev F.; R346K Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions with Monoclonal antibodies from Class 2: A free energy perturbation study. J Chem Inf Model 2022,62(3),627-631","journal-title":"J Chem Inf Model"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5702","DOI":"10.1021\/jacs.1c11554","volume":"144","author":"Han Y.","year":"2022","unstructured":"Han Y.; Yang Z.; Hu H.; Zhang H.; Chen L.; Li K.; Kong L.; Wang Q.; Liu B.; Wang M.; Lin J.; Chen P.R.; Covalently engineered protein minibinders with enhanced neutralization efficacy against escaping SARS-CoV-2 Variants. J Am Chem Soc 2022,144(13),5702-5707","journal-title":"J Am Chem Soc"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.chom.2020.11.007","volume":"29","author":"Greaney A.J.","year":"2021","unstructured":"Greaney A.J.; Starr T.N.; Gilchuk P.; Zost S.J.; Binshtein E.; Loes A.N.; Hilton S.K.; Huddleston J.; Eguia R.; Crawford K.H.D.; Dingens A.S.; Nargi R.S.; Sutton R.E.; Suryadevara N.; Rothlauf P.W.; Liu Z.; Whelan S.P.J.; Carnahan R.H.; Crowe J.E.; Bloom J.D.; Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 2021,29(1),44-57.e9","journal-title":"Cell Host Microbe"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"Harvey W.T.","year":"2021","unstructured":"Harvey W.T.; Carabelli A.M.; Jackson B.; Gupta R.K.; Thomson E.C.; Harrison E.M.; Ludden C.; Reeve R.; Rambaut A.; Peacock S.J.; Robertson D.L.; SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021,19(7),409-424","journal-title":"Nat Rev Microbiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/jmv.27491","volume":"94","author":"Gao S.J.","year":"2022","unstructured":"Gao S.J.; Guo H.; Luo G.; Omicron variant (B.1.1.529) of SARS\u2010CoV\u20102, a global urgent public health alert!. J Med Virol 2022,94(4),1255-1256","journal-title":"J Med Virol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","volume":"398","author":"Karim S.S.A.","year":"2021","unstructured":"Karim S.S.A.; Karim Q.A.; Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet 2021,398(10317),2126-2128","journal-title":"Lancet"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"Meng B.","year":"2022","unstructured":"Meng B.; Abdullahi A.; Ferreira I.A.T.M.; Goonawardane N.; Saito A.; Kimura I.; Yamasoba D.; Gerber P.P.; Fatihi S.; Rathore S.; Zepeda S.K.; Papa G.; Kemp S.A.; Ikeda T.; Toyoda M.; Tan T.S.; Kuramochi J.; Mitsunaga S.; Ueno T.; Shirakawa K.; Takaori-Kondo A.; Brevini T.; Mallery D.L.; Charles O.J.; Baker S.; Dougan G.; Hess C.; Kingston N.; Lehner P.J.; Lyons P.A.; Matheson N.J.; Ouwehand W.H.; Saunders C.; Summers C.; Thaventhiran J.E.D.; Toshner M.; Weekes M.P.; Maxwell P.; Shaw A.; Bucke A.; Calder J.; Canna L.; Domingo J.; Elmer A.; Fuller S.; Harris J.; Hewitt S.; Kennet J.; Jose S.; Kourampa J.; Meadows A.; O\u2019Brien C.; Price J.; Publico C.; Rastall R.; Ribeiro C.; Rowlands J.; Ruffolo V.; Tordesillas H.; Bullman B.; Dunmore B.J.; Gr\u00e4f S.; Hodgson J.; Huang C.; Hunter K.; Jones E.; Legchenko E.; Matara C.; Martin J.; Mescia F.; O\u2019Donnell C.; Pointon L.; Shih J.; Sutcliffe R.; Tilly T.; Treacy C.; Tong Z.; Wood J.; Wylot M.; Betancourt A.; Bower G.; Cossetti C.; De Sa A.; Epping M.; Fawke S.; Gleadall N.; Grenfell R.; Hinch A.; Jackson S.; Jarvis I.; Krishna B.; Nice F.; Omarjee O.; Perera M.; Potts M.; Richoz N.; Romashova V.; Stefanucci L.; Strezlecki M.; Turner L.; De Bie E.M.D.D.; Bunclark K.; Josipovic M.; Mackay M.; Butcher H.; Caputo D.; Chandler M.; Chinnery P.; Clapham-Riley D.; Dewhurst E.; Fernandez C.; Furlong A.; Graves B.; Gray J.; Hein S.; Ivers T.; Le Gresley E.; Linger R.; Kasanicki M.; King R.; Kingston N.; Meloy S.; Moulton A.; Muldoon F.; Ovington N.; Papadia S.; Penkett C.J.; Phelan I.; Ranganath V.; Paraschiv R.; Sage A.; Sambrook J.; Scholtes I.; Schon K.; Stark H.; Stirrups K.E.; Townsend P.; Walker N.; Webster J.; Butlertanaka E.P.; Tanaka Y.L.; Ito J.; Uriu K.; Kosugi Y.; Suganami M.; Oide A.; Yokoyama M.; Chiba M.; Motozono C.; Nasser H.; Shimizu R.; Kitazato K.; Hasebe H.; Irie T.; Nakagawa S.; Wu J.; Takahashi M.; Fukuhara T.; Shimizu K.; Tsushima K.; Kubo H.; Kazuma Y.; Nomura R.; Horisawa Y.; Nagata K.; Kawai Y.; Yanagida Y.; Tashiro Y.; Tokunaga K.; Ozono S.; Kawabata R.; Morizako N.; Sadamasu K.; Asakura H.; Nagashima M.; Yoshimura K.; C\u00e1rdenas P.; Mu\u00f1oz E.; Barragan V.; M\u00e1rquez S.; Prado-Vivar B.; Becerra-Wong M.; Caravajal M.; Trueba G.; Rojas-Silva P.; Grunauer M.; Gutierrez B.; Guadalupe J.J.; Fern\u00e1ndez-Cadena J.C.; Andrade-Molina D.; Baldeon M.; Pinos A.; Bowen J.E.; Joshi A.; Walls A.C.; Jackson L.; Martin D.; Smith K.G.C.; Bradley J.; Briggs J.A.G.; Choi J.; Madissoon E.; Meyer K.B.; Mlcochova P.; Ceron-Gutierrez L.; Doffinger R.; Teichmann S.A.; Fisher A.J.; Pizzuto M.S.; de Marco A.; Corti D.; Hosmillo M.; Lee J.H.; James L.C.; Thukral L.; Veesler D.; Sigal A.; Sampaziotis F.; Goodfellow I.G.; Matheson N.J.; Sato K.; Gupta R.K.; Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022,603(7902),706-714","journal-title":"Nature"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"110729","DOI":"10.1016\/j.celrep.2022.110729","volume":"39","author":"Zhang J.","year":"2022","unstructured":"Zhang J.; Cai Y.; Lavine C.L.; Peng H.; Zhu H.; Anand K.; Tong P.; Gautam A.; Mayer M.L.; Rits-Volloch S.; Wang S.; Sliz P.; Wesemann D.R.; Yang W.; Seaman M.S.; Lu J.; Xiao T.; Chen B.; Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Cell Rep 2022,39(4),110729","journal-title":"Cell Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"Hoffmann M.","year":"2022","unstructured":"Hoffmann M.; Kr\u00fcger N.; Schulz S.; Cossmann A.; Rocha C.; Kempf A.; Nehlmeier I.; Graichen L.; Moldenhauer A.S.; Winkler M.S.; Lier M.; Dopfer-Jablonka A.; J\u00e4ck H.M.; Behrens G.M.N.; P\u00f6hlmann S.; The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 2022,185(3),447-456.e11","journal-title":"Cell"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"110770","DOI":"10.1016\/j.celrep.2022.110770","volume":"39","author":"Guo H.","year":"2022","unstructured":"Guo H.; Gao Y.; Li T.; Li T.; Lu Y.; Zheng L.; Liu Y.; Yang T.; Luo F.; Song S.; Wang W.; Yang X.; Nguyen H.C.; Zhang H.; Huang A.; Jin A.; Yang H.; Rao Z.; Ji X.; Structures of Omicron spike complexes and implications for neutralizing antibody development. Cell Rep 2022,39(5),110770","journal-title":"Cell Rep"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.cell.2022.06.023","volume":"185","author":"Li L.","year":"2022","unstructured":"Li L.; Liao H.; Meng Y.; Li W.; Han P.; Liu K.; Wang Q.; Li D.; Zhang Y.; Wang L.; Fan Z.; Zhang Y.; Wang Q.; Zhao X.; Sun Y.; Huang N.; Qi J.; Gao G.F.; Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Cell 2022,185(16),2952-2960.e10","journal-title":"Cell"},{"key":"ref=27","unstructured":"Epidemiological update: SARS-CoV-2 Omicron sublineages BA.4 and BA.5. ECDCAvailable From:  [Accessed on Jul 12, 2022]."},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"101306","DOI":"10.1016\/j.bbrep.2022.101306","volume":"31","author":"Koshikawa T.","year":"2022","unstructured":"Koshikawa T.; Miyoshi H.; High-resolution melting analysis to discriminate between the SARS-CoV-2 Omicron variants BA.1 and BA.2. Biochem Biophys Rep 2022,31,101306","journal-title":"Biochem Biophys Rep"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","volume":"22","author":"Arora P.","year":"2022","unstructured":"Arora P.; Kempf A.; Nehlmeier I.; Schulz S.R.; Cossmann A.; Stankov M.V.; J\u00e4ck H.M.; Behrens G.M.N.; P\u00f6hlmann S.; Hoffmann M.; Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect Dis 2022,22(8),1117-1118","journal-title":"Lancet Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e20201181","DOI":"10.1084\/jem.20201181","volume":"217","author":"Schmidt F.","year":"2020","unstructured":"Schmidt F.; Weisblum Y.; Muecksch F.; Hoffmann H.H.; Michailidis E.; Lorenzi J.C.C.; Mendoza P.; Rutkowska M.; Bednarski E.; Gaebler C.; Agudelo M.; Cho A.; Wang Z.; Gazumyan A.; Cipolla M.; Caskey M.; Robbiani D.F.; Nussenzweig M.C.; Rice C.M.; Hatziioannou T.; Bieniasz P.D.; Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med 2020,217(11),e20201181","journal-title":"J Exp Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"100997","DOI":"10.1016\/j.nmni.2022.100997","volume":"48","author":"Dhawan M.","year":"2022","unstructured":"Dhawan M.; Saied A.A.; Emran T.B.; Choudhary O.P.; Emergence of omicron variant\u2019s sublineages BA.4 and BA.5: Risks assessment and possible countermeasures. New Microbes New Infect 2022,48,100997","journal-title":"New Microbes New Infect"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"104076","DOI":"10.1016\/j.isci.2022.104076","volume":"25","author":"Mader A.L.","year":"2022","unstructured":"Mader A.L.; Tydykov L.; Gl\u00fcck V.; Bertok M.; Weidlich T.; Gottwald C.; Stefl A.; Vogel M.; Plentz A.; K\u00f6stler J.; Salzberger B.; Wenzel J.J.; Niller H.H.; Jantsch J.; Wagner R.; Schmidt B.; Gl\u00fcck T.; Gessner A.; Peterhoff D.; Omicron\u2019s binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals. iScience 2022,25(4),104076","journal-title":"iScience"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"Tuekprakhon A.","year":"2022","unstructured":"Tuekprakhon A.; Nutalai R.; Dijokaite-Guraliuc A.; Zhou D.; Ginn H.M.; Selvaraj M.; Liu C.; Mentzer A.J.; Supasa P.; Duyvesteyn H.M.E.; Das R.; Skelly D.; Ritter T.G.; Amini A.; Bibi S.; Adele S.; Johnson S.A.; Constantinides B.; Webster H.; Temperton N.; Klenerman P.; Barnes E.; Dunachie S.J.; Crook D.; Pollard A.J.; Lambe T.; Goulder P.; Paterson N.G.; Williams M.A.; Hall D.R.; Fry E.E.; Huo J.; Mongkolsapaya J.; Ren J.; Stuart D.I.; Screaton G.R.; Conlon C.; Deeks A.; Frater J.; Frending L.; Gardiner S.; J\u00e4ms\u00e9n A.; Jeffery K.; Malone T.; Phillips E.; Rothwell L.; Stafford L.; Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 2022,185(14),2422-2433.e13","journal-title":"Cell"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.immuni.2022.06.005","volume":"55","author":"Huang M.","year":"2022","unstructured":"Huang M.; Wu L.; Zheng A.; Xie Y.; He Q.; Rong X.; Han P.; Du P.; Han P.; Zhang Z.; Zhao R.; Jia Y.; Li L.; Bai B.; Hu Z.; Hu S.; Niu S.; Hu Y.; Liu H.; Liu B.; Cui K.; Li W.; Zhao X.; Liu K.; Qi J.; Wang Q.; Gao G.F.; Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1\/BA.1.1\/BA.2\/BA.3. Immunity 2022,55(8),1501-1514.e3","journal-title":"Immunity"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"111009","DOI":"10.1016\/j.celrep.2022.111009","volume":"39","author":"Stalls V.","year":"2022","unstructured":"Stalls V.; Lindenberger J.; Gobeil S.M.C.; Henderson R.; Parks R.; Barr M.; Deyton M.; Martin M.; Janowska K.; Huang X.; May A.; Speakman M.; Beaudoin E.; Kraft B.; Lu X.; Edwards R.J.; Eaton A.; Montefiori D.C.; Williams W.B.; Saunders K.O.; Wiehe K.; Haynes B.F.; Acharya P.; Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Cell Rep 2022,39(13),111009","journal-title":"Cell Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"106698","DOI":"10.1016\/j.ijsu.2022.106698","volume":"103","author":"Mohapatra R.K.","year":"2022","unstructured":"Mohapatra R.K.; Kandi V.; Sarangi A.K.; Verma S.; Tuli H.S.; Chakraborty S.; Chakraborty C.; Dhama K.; The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic \u2013 Correspondence. Int J Surg 2022,103,106698","journal-title":"Int J Surg"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"Gordon D.E.","year":"2020","unstructured":"Gordon D.E.; Jang G.M.; Bouhaddou M.; Xu J.; Obernier K.; White K.M.; O\u2019Meara M.J.; Rezelj V.V.; Guo J.Z.; Swaney D.L.; Tummino T.A.; H\u00fcttenhain R.; Kaake R.M.; Richards A.L.; Tutuncuoglu B.; Foussard H.; Batra J.; Haas K.; Modak M.; Kim M.; Haas P.; Polacco B.J.; Braberg H.; Fabius J.M.; Eckhardt M.; Soucheray M.; Bennett M.J.; Cakir M.; McGregor M.J.; Li Q.; Meyer B.; Roesch F.; Vallet T.; Mac Kain A.; Miorin L.; Moreno E.; Naing Z.Z.C.; Zhou Y.; Peng S.; Shi Y.; Zhang Z.; Shen W.; Kirby I.T.; Melnyk J.E.; Chorba J.S.; Lou K.; Dai S.A.; Barrio-Hernandez I.; Memon D.; Hernandez-Armenta C.; Lyu J.; Mathy C.J.P.; Perica T.; Pilla K.B.; Ganesan S.J.; Saltzberg D.J.; Rakesh R.; Liu X.; Rosenthal S.B.; Calviello L.; Venkataramanan S.; Liboy-Lugo J.; Lin Y.; Huang X.P.; Liu Y.F.; Wankowicz S.A.; Bohn M.; Safari M.; Ugur F.S.; Koh C.; Savar N.S.; Tran Q.D.; Shengjuler D.; Fletcher S.J.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klippsten S.; Sharp P.P.; Wenzell N.A.; Kuzuoglu-Ozturk D.; Wang H.Y.; Trenker R.; Young J.M.; Cavero D.A.; Hiatt J.; Roth T.L.; Rathore U.; Subramanian A.; Noack J.; Hubert M.; Stroud R.M.; Frankel A.D.; Rosenberg O.S.; Verba K.A.; Agard D.A.; Ott M.; Emerman M.; Jura N.; von Zastrow M.; Verdin E.; Ashworth A.; Schwartz O.; d\u2019Enfert C.; Mukherjee S.; Jacobson M.; Malik H.S.; Fujimori D.G.; Ideker T.; Craik C.S.; Floor S.N.; Fraser J.S.; Gross J.D.; Sali A.; Roth B.L.; Ruggero D.; Taunton J.; Kortemme T.; Beltrao P.; Vignuzzi M.; Garc\u00eda-Sastre A.; Shokat K.M.; Shoichet B.K.; Krogan N.J.A.; SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nat 2020,583,459-468","journal-title":"Nat"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00441155","volume":"138","author":"Braga S.","year":"1982","unstructured":"Braga S.; Schmidt A.; Clinical and cytogenetic spectrum of duplication 3p. Eur J Pediatr 1982,138(2),195-197","journal-title":"Eur J Pediatr"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","volume":"9","author":"Chan J.F.W.","year":"2020","unstructured":"Chan J.F.W.; Kok K.H.; Zhu Z.; Chu H.; To K.K.W.; Yuan S.; Yuen K.Y.; Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020,9(1),221-236","journal-title":"Emerg Microbes Infect"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"Fehr A.R.","year":"2015","unstructured":"Fehr A.R.; Perlman S.; Coronaviruses: An overview of their replication and pathogenesis. Methods Mol Biol 2015,1282,1-23","journal-title":"Methods Mol Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.coviro.2021.08.010","volume":"50","author":"Zhang J.","year":"2021","unstructured":"Zhang J.; Xiao T.; Cai Y.; Chen B.; Structure of SARS-CoV-2 spike protein. Curr Opin Virol 2021,50,173-182","journal-title":"Curr Opin Virol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"200209","DOI":"10.1098\/rsob.200209","volume":"10","author":"Duart G.","year":"2020","unstructured":"Duart G.; Garc\u00eda-Murria M.J.; Grau B.; Acosta-C\u00e1ceres J.M.; Mart\u00ednez-Gil L.; Mingarro I.; SARS-CoV-2 envelope protein topology in eukaryotic membranes. Open Biol 2020,10(9),200209","journal-title":"Open Biol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.sjbs.2020.12.053","volume":"28","author":"Al-Qaaneh A.M.","year":"2021","unstructured":"Al-Qaaneh A.M.; Alshammari T.; Aldahhan R.; Aldossary H.; Alkhalifah Z.A.; Borgio J.F.; Genome composition and genetic characterization of SARS-CoV-2. Saudi J Biol Sci 2021,28(3),1978-1989","journal-title":"Saudi J Biol Sci"},{"key":"ref=44","author":"Bianchi M.","year":"2020","unstructured":"Bianchi M.; Benvenuto D.; Giovanetti M.; Angeletti S.; Ciccozzi M.; Pascarella S.; Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? Biomed Res Int 2020","journal-title":"Biomed Res Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbrc.2020.04.136","volume":"527","author":"Zeng W.","year":"2020","unstructured":"Zeng W.; Liu G.; Ma H.; Zhao D.; Yang Y.; Liu M.; Mohammed A.; Zhao C.; Yang Y.; Xie J.; Ding C.; Ma X.; Weng J.; Gao Y.; He H.; Jin T.; Biochemical characterization of SARS-CoV-2 nucleocapsid protein. Biochem Biophys Res Commun 2020,527(3),618-623","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1016\/j.vaccine.2006.01.058","volume":"24","author":"Liu S.","year":"2006","unstructured":"Liu S.; Leng C.; Lien S.; Chi H.; Huang C.; Lin C.; Lian W.; Chen C.; Hsieh S.; Chong P.; Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 2006,24(16),3100-3108","journal-title":"Vaccine"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"115745","DOI":"10.1016\/j.bmc.2020.115745","volume":"28","author":"Silva L.R.","year":"2020","unstructured":"Silva L.R.; da Silva Santos-J\u00fanior P.F.; de Andrade Brand\u00e3o J.; Anderson L.; Bassi \u00ca.J.; Xavier de Ara\u00fajo-J\u00fanior J.; Cardoso S.H.; da Silva-J\u00fanior E.F.; Druggable targets from coronaviruses for designing new antiviral drugs. Bioorg Med Chem 2020,28(22),115745","journal-title":"Bioorg Med Chem"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"Anand K.","year":"2003","unstructured":"Anand K.; Ziebuhr J.; Wadhwani P.; Mesters J.R.; Hilgenfeld R.; Qamar T.; Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. Science 2003,300,1763-1767","journal-title":"Science"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jpha.2020.03.009","volume":"10","author":"Tahir ul Qamar M.","year":"2020","unstructured":"Tahir ul Qamar M.; Alqahtani S.M.; Alamri M.A.; Chen L.L.; Structural Basis of SARS-CoV-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants. J Pharm Anal 2020,10(4),313-319","journal-title":"J Pharm Anal"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrmicro2147","volume":"7","author":"Perlman S.","year":"2009","unstructured":"Perlman S.; Netland J.; Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 2009,7(6),439-450","journal-title":"Nat Rev Microbiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","volume":"290","author":"Tomar S.","year":"2015","unstructured":"Tomar S.; Johnston M.L.; St John S.E.; Osswald H.L.; Nyalapatla P.R.; Paul L.N.; Ghosh A.K.; Denison M.R.; Mesecar A.D.; Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): Implications for nsp5 regulation and the development of antivirals. J Biol Chem 2015,290(32),19403-19422","journal-title":"J Biol Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"13600","DOI":"10.1128\/JVI.78.24.13600-13612.2004","volume":"78","author":"Harcourt B.H.","year":"2004","unstructured":"Harcourt B.H.; Jukneliene D.; Kanjanahaluethai A.; Bechill J.; Severson K.M.; Smith C.M.; Rota P.A.; Baker S.C.; Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol 2004,78(24),13600-13612","journal-title":"J Virol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"B\u00e1ez-Santos Y.M.","year":"2015","unstructured":"B\u00e1ez-Santos Y.M.; St John S.E.; Mesecar A.D.; The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015,115,21-38","journal-title":"Antiviral Res"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-0-387-33012-9_5","volume":"581","author":"Barretto N.","year":"2006","unstructured":"Barretto N.; Jukneliene D.; Ratia K.; Chen Z.; Mesecar A.D.; Baker S.C.; Deubiquitinating activity of the SARS-CoV papain-like protease. Adv Exp Med Biol 2006,581,37-41","journal-title":"Adv Exp Med Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"15199","DOI":"10.1128\/JVI.79.24.15199-15208.2005","volume":"79","author":"Lindner H.A.","year":"2005","unstructured":"Lindner H.A.; Fotouhi-Ardakani N.; Lytvyn V.; Lachance P.; Sulea T.; M\u00e9nard R.; The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 2005,79(24),15199-15208","journal-title":"J Virol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1128\/JVI.02220-08","volume":"83","author":"Frieman M.","year":"2009","unstructured":"Frieman M.; Ratia K.; Johnston R.E.; Mesecar A.D.; Baric R.S.; Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 2009,83(13),6689-6705","journal-title":"J Virol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1073\/pnas.0510851103","volume":"103","author":"Ratia K.","year":"2006","unstructured":"Ratia K.; Saikatendu K.S.; Santarsiero B.D.; Barretto N.; Baker S.C.; Stevens R.C.; Mesecar A.D.; Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 2006,103(15),5717-5722","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.antiviral.2014.06.011","volume":"109","author":"Lei J.","year":"2014","unstructured":"Lei J.; Mesters J.R.; Drosten C.; Anem\u00fcller S.; Ma Q.; Hilgenfeld R.; Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res 2014,109,72-82","journal-title":"Antiviral Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"Tan H.","year":"2022","unstructured":"Tan H.; Hu Y.; Jadhav P.; Tan B.; Wang J.; Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. J Med Chem 2022,65(11),7561-7580","journal-title":"J Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2174\/1389450122666210809090909","volume":"23","author":"dos Santos Nascimento I.J.","year":"2022","unstructured":"dos Santos Nascimento I.J.; da Silva-J\u00fanior E.F.; de Aquino T.M.; Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses. Curr Drug Targets 2022,23(3),240-259","journal-title":"Curr Drug Targets"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/9789815051308122010007","author":"Santos-J\u00fanior P.F. da S.","year":"2022","unstructured":"Santos-J\u00fanior P.F. da S.; Ara\u00fajo-J\u00fanior J.X.;  Pharmaceut Target Coronaviruses 2022,158-188","journal-title":"Pharmaceut Target Coronaviruses"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/9789815051308122010003","author":"Nascimento I.J. dos S.","year":"2022","unstructured":"Nascimento I.J. dos S.; de Aquino T.M.; da Silva-J\u00fanior E.F.;  Pharmaceuticals for Targeting Coronaviruses 2022,1-61","journal-title":"Pharmaceuticals for Targeting Coronaviruses"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2174\/9789811412387120080004","author":"Fernando da Silva Santos-Junior P.","year":"2020","unstructured":"Fernando da Silva Santos-Junior P.; Jose dos Santos Nascimento I.; Mendonca de Aquino T.; Xavier de Araujo-Junior J.; Ferreira da Silva-Junior E.;  Frontiers in Anti-Infective Drug Discovery 2020,35-90","journal-title":"Frontiers in Anti-Infective Drug Discovery"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2174\/1875533XMTA5rMDYp5","volume":"28","author":"dos Santos Nascimento I.J.","year":"2021","unstructured":"dos Santos Nascimento I.J.; de Aquino T.M.; da Silva-J\u00fanior E.F.; Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. Curr Med Chem 2021,28(15),2887-2942","journal-title":"Curr Med Chem"},{"author":"Milken I.","key":"ref=65","unstructured":"Milken I.; COVID-19 Treatment and Vaccine Tracker. Available From:  [Accessed on Jul 8, 2022]."},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jphs.2022.04.007","volume":"149","author":"Kato Y.","year":"2022","unstructured":"Kato Y.; Nishiyama K.; Nishimura A.; Noda T.; Okabe K.; Kusakabe T.; Kanda Y.; Nishida M.; Drug repurposing for the treatment of COVID-19. J Pharmacol Sci 2022,149(3),108-114","journal-title":"J Pharmacol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.drudis.2022.02.004","volume":"27","author":"Kumar S.","year":"2022","unstructured":"Kumar S.; Kovalenko S.; Bhardwaj S.; Sethi A.; Gorobets N.Y.; Desenko S.M.; Poonam ; Rathi B.;  Drug repurposing against SARS-CoV-2 using computational approaches. Drug Discov Today 2022,27(7),2015-2027","journal-title":"Drug Discov Today"},{"key":"ref=68","unstructured":"Antiviral Therapy | COVID-19 Treatment Guidelines. NIHAvailable From:  [Accessed on Jul 8, 2022]."},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"9253","DOI":"10.18632\/aging.202867","volume":"13","author":"Jie X.","year":"2021","unstructured":"Jie X.; Hongmei Y.; Ping F.; Kuikui Z.; Bohan Y.; Rui M.; Beneficial effect of Arbidol in the management of COVID-19 infection. Aging 2021,13(7),9253-9264","journal-title":"Aging"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12879-021-06164-x","volume":"21","author":"Manabe T.","year":"2021","unstructured":"Manabe T.; Kambayashi D.; Akatsu H.; Kudo K.; Favipiravir for the treatment of patients with COVID-19: A systematic review and meta-analysis. BMC Infect Dis 2021,21(1),489","journal-title":"BMC Infect Dis"},{"key":"ref=71","unstructured":"Pfizer Starts Global Phase 2\/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults. Pfizer.Available From:  [Accessed on Jul 10, 2022]."},{"key":"ref=72","first-page":"44","volume":"99","author":"Halford B.","year":"2021","unstructured":"Halford B.; Pills to End the Pandemic. CandEN Glob. Interprise 2021,99,44-45","journal-title":"Interprise"},{"key":"ref=73","unstructured":"Atea\u2019s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis. Available From:  [Accessed on Jul 10, 2022]."},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3389\/fmicb.2020.02112","volume":"11","author":"Saputri D.S.","year":"2020","unstructured":"Saputri D.S.; Li S.; van Eerden F.J.; Rozewicki J.; Xu Z.; Ismanto H.S.; Davila A.; Teraguchi S.; Katoh K.; Standley D.M.; Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution. Front Microbiol 2020,11,2112","journal-title":"Front Microbiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13054-021-03662-x","volume":"25","author":"Khateeb J.","year":"2021","unstructured":"Khateeb J.; Li Y.; Zhang H.; Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care 2021,25(1),244","journal-title":"Crit Care"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"29588","DOI":"10.1074\/jbc.M500662200","volume":"280","author":"Qu X.X.","year":"2005","unstructured":"Qu X.X.; Hao P.; Song X.J.; Jiang S.M.; Liu Y.X.; Wang P.G.; Rao X.; Song H.D.; Wang S.Y.; Zuo Y.; Zheng A.H.; Luo M.; Wang H.L.; Deng F.; Wang H.Z.; Hu Z.H.; Ding M.X.; Zhao G.P.; Deng H.K.; Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem 2005,280(33),29588-29595","journal-title":"J Biol Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1073\/pnas.0409608102","volume":"102","author":"Song H.D.","year":"2005","unstructured":"Song H.D.; Tu C.C.; Zhang G.W.; Wang S.Y.; Zheng K.; Lei L.C.; Chen Q.X.; Gao Y.W.; Zhou H.Q.; Xiang H.; Zheng H.J.; Chern S.W.W.; Cheng F.; Pan C.M.; Xuan H.; Chen S.J.; Luo H.M.; Zhou D.H.; Liu Y.F.; He J.F.; Qin P.Z.; Li L.H.; Ren Y.Q.; Liang W.J.; Yu Y.D.; Anderson L.; Wang M.; Xu R.H.; Wu X.W.; Zheng H.Y.; Chen J.D.; Liang G.; Gao Y.; Liao M.; Fang L.; Jiang L.Y.; Li H.; Chen F.; Di B.; He L.J.; Lin J.Y.; Tong S.; Kong X.; Du L.; Hao P.; Tang H.; Bernini A.; Yu X.J.; Spiga O.; Guo Z.M.; Pan H.Y.; He W.Z.; Manuguerra J.C.; Fontanet A.; Danchin A.; Niccolai N.; Li Y.X.; Wu C.I.; Zhao G.P.; Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA 2005,102(7),2430-2435","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"Hoffmann M.","year":"2020","unstructured":"Hoffmann M.; Kleine-Weber H.; Schroeder S.; Kr\u00fcger N.; Herrler T.; Erichsen S.; Schiergens T.S.; Herrler G.; Wu N.H.; Nitsche A.; M\u00fcller M.A.; Drosten C.; P\u00f6hlmann S.; SARS-CoV-2 Cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020,181(2),271-280.e8","journal-title":"Cell"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"Walls A.C.","year":"2020","unstructured":"Walls A.C.; Park Y.J.; Tortorici M.A.; Wall A.; McGuire A.T.; Veesler D.; Structure, function, and antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020,183(6),1735","journal-title":"Cell"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1021\/acs.jpclett.2c00469","volume":"13","author":"Chen J.","year":"2022","unstructured":"Chen J.; Wei G.W.; Omicron BA.2 (B.1.1.529.2): High potential for becoming the next dominant variant. J Phys Chem Lett 2022,13(17),3840-3849","journal-title":"J Phys Chem Lett"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.csbj.2022.02.015","volume":"20","author":"Socher E.","year":"2022","unstructured":"Socher E.; Heger L.; Paulsen F.; Zunke F.; Arnold P.; Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike \u2013 ACE2 complexes reveal distinct changes between both variants. Comput Struct Biotechnol J 2022,20,1168-1176","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1021\/acs.jcim.2c00124","volume":"62","author":"Verkhivker G.M.","year":"2022","unstructured":"Verkhivker G.M.; Agajanian S.; Kassab R.; Krishnan K.; Landscape-based protein stability analysis and network modeling of multiple conformational states of the SARS-CoV-2 Spike D614G Mutant: Conformational plasticity and frustration-induced allostery as energetic drivers of highly transmissible spike variants. J Chem Inf Model 2022,62(8),1956-1978","journal-title":"J Chem Inf Model"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1021\/acs.jpclett.2c00423","volume":"13","author":"Jawad B.","year":"2022","unstructured":"Jawad B.; Adhikari P.; Podgornik R.; Ching W.Y.; Binding interactions between receptor-binding domain of spike protein and human angiotensin converting enzyme-2 in omicron variant. J Phys Chem Lett 2022,13(17),3915-3921","journal-title":"J Phys Chem Lett"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1021\/acs.jcim.2c00100","volume":"62","author":"Hwang S.","year":"2022","unstructured":"Hwang S.; Baek S.H.; Park D.; Interaction analysis of the spike protein of delta and omicron variants of SARS-CoV-2 with hACE2 and eight monoclonal antibodies using the fragment molecular orbital method. J Chem Inf Model 2022,62(7),1771-1782","journal-title":"J Chem Inf Model"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"Wrapp D.","year":"2020","unstructured":"Wrapp D.; Wang N.; Corbett K.S.; Goldsmith J.A.; Hsieh C.-L.; Abiona O.; Graham B.S.; McLellan J.S.; Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. Science 2020,367(6483),1260-1263","journal-title":"Science"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"15092","DOI":"10.1038\/ncomms15092","volume":"8","author":"Yuan Y.","year":"2017","unstructured":"Yuan Y.; Cao D.; Zhang Y.; Ma J.; Qi J.; Wang Q.; Lu G.; Wu Y.; Yan J.; Shi Y.; Zhang X.; Gao G.F.; Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun 2017,8(1),15092","journal-title":"Nat Commun"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ijbiomac.2022.01.059","volume":"200","author":"Khan A.","year":"2022","unstructured":"Khan A.; Waris H.; Rafique M.; Suleman M.; Mohammad A.; Ali S.S.; Khan T.; Waheed Y.; Liao C.; Wei D.Q.; The Omicron (B.1.1.529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: Insights from structural and simulation data. Int J Biol Macromol 2022,200,438-448","journal-title":"Int J Biol Macromol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"eabf3671","DOI":"10.1126\/sciadv.abf3671","volume":"7","author":"Mansbach R.A.","year":"2021","unstructured":"Mansbach R.A.; Chakraborty S.; Nguyen K.; Montefiori D.C.; Korber B.; Gnanakaran S.; The SARS-CoV-2 Spike variant D614G favors an open conformational state. Sci Adv 2021,7(16),eabf3671","journal-title":"Sci Adv"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1056\/NEJMsr2105280","volume":"385","author":"Krause P.R.","year":"2021","unstructured":"Krause P.R.; Fleming T.R.; Longini I.M.; Peto R.; Briand S.; Heymann D.L.; Beral V.; Snape M.D.; Rees H.; Ropero A.M.; Balicer R.D.; Cramer J.P.; Mu\u00f1oz-Fontela C.; Gruber M.; Gaspar R.; Singh J.A.; Subbarao K.; Van Kerkhove M.D.; Swaminathan S.; Ryan M.J.; Henao-Restrepo A.M.; SARS-CoV-2 Variants and Vaccines. N Engl J Med 2021,385(2),179-186","journal-title":"N Engl J Med"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"408","DOI":"10.14348\/molcells.2021.0026","volume":"44","author":"Shah M.","year":"2021","unstructured":"Shah M.; Woo H.G.; Molecular Perspectives of SARS-CoV-2: Pathology, immune evasion, and therapeutic interventions. Mol Cells 2021,44(6),408-421","journal-title":"Mol Cells"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"Lan J.","year":"2020","unstructured":"Lan J.; Ge J.; Yu J.; Shan S.; Zhou H.; Fan S.; Zhang Q.; Shi X.; Wang Q.; Zhang L.; Wang X.; Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020,581(7807),215-220","journal-title":"Nature"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"Shang J.","year":"2020","unstructured":"Shang J.; Ye G.; Shi K.; Wan Y.; Luo C.; Aihara H.; Geng Q.; Auerbach A.; Li F.; Structural basis of receptor recognition by SARS-CoV-2. Nature 2020,581(7807),221-224","journal-title":"Nature"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1021\/cc0500607","volume":"7","author":"Hu H.","year":"2005","unstructured":"Hu H.; Li L.; Kao R.Y.; Kou B.; Wang Z.; Zhang L.; Zhang H.; Hao Z.; Tsui W.H.; Ni A.; Cui L.; Fan B.; Guo F.; Rao S.; Jiang C.; Li Q.; Sun M.; He W.; Liu G.; Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. J Comb Chem 2005,7(5),648-656","journal-title":"J Comb Chem"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.virol.2006.01.029","volume":"350","author":"Han D.P.","year":"2006","unstructured":"Han D.P.; Penn-Nicholson A.; Cho M.W.; Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology 2006,350(1),15-25","journal-title":"Virology"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/j.csbj.2022.04.030","volume":"20","author":"Shah M.","year":"2022","unstructured":"Shah M.; Ung Moon S.; Hyun Kim J.; Thanh Thao T.; Goo Woo H.; SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Comput Struct Biotechnol J 2022,20,2042-2056","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Liu Z.","year":"2020","unstructured":"Liu Z.; Xu W.; Xia S.; Gu C.; Wang X.; Wang Q.; Zhou J.; Wu Y.; Cai X.; Qu D.; Ying T.; Xie Y.; Lu L.; Yuan Z.; Jiang S.; RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther 2020,5(1),282","journal-title":"Signal Transduct Target Ther"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"Yang J.","year":"2020","unstructured":"Yang J.; Wang W.; Chen Z.; Lu S.; Yang F.; Bi Z.; Bao L.; Mo F.; Li X.; Huang Y.; Hong W.; Yang Y.; Zhao Y.; Ye F.; Lin S.; Deng W.; Chen H.; Lei H.; Zhang Z.; Luo M.; Gao H.; Zheng Y.; Gong Y.; Jiang X.; Xu Y.; Lv Q.; Li D.; Wang M.; Li F.; Wang S.; Wang G.; Yu P.; Qu Y.; Yang L.; Deng H.; Tong A.; Li J.; Wang Z.; Yang J.; Shen G.; Zhao Z.; Li Y.; Luo J.; Liu H.; Yu W.; Yang M.; Xu J.; Wang J.; Li H.; Wang H.; Kuang D.; Lin P.; Hu Z.; Guo W.; Cheng W.; He Y.; Song X.; Chen C.; Xue Z.; Yao S.; Chen L.; Ma X.; Chen S.; Gou M.; Huang W.; Wang Y.; Fan C.; Tian Z.; Shi M.; Wang F.S.; Dai L.; Wu M.; Li G.; Wang G.; Peng Y.; Qian Z.; Huang C.; Lau J.Y.N.; Yang Z.; Wei Y.; Cen X.; Peng X.; Qin C.; Zhang K.; Lu G.; Wei X.; A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 2020,586(7830),572-577","journal-title":"Nature"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"Dai L.","year":"2020","unstructured":"Dai L.; Zheng T.; Xu K.; Han Y.; Xu L.; Huang E.; An Y.; Cheng Y.; Li S.; Liu M.; Yang M.; Li Y.; Cheng H.; Yuan Y.; Zhang W.; Ke C.; Wong G.; Qi J.; Qin C.; Yan J.; Gao G.F.; A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 2020,182(3),722-733.e11","journal-title":"Cell"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"Walls A.C.","year":"2020","unstructured":"Walls A.C.; Fiala B.; Sch\u00e4fer A.; Wrenn S.; Pham M.N.; Murphy M.; Tse L.V.; Shehata L.; O\u2019Connor M.A.; Chen C.; Navarro M.J.; Miranda M.C.; Pettie D.; Ravichandran R.; Kraft J.C.; Ogohara C.; Palser A.; Chalk S.; Lee E.C.; Guerriero K.; Kepl E.; Chow C.M.; Sydeman C.; Hodge E.A.; Brown B.; Fuller J.T.; Dinnon K.H.; Gralinski L.E.; Leist S.R.; Gully K.L.; Lewis T.B.; Guttman M.; Chu H.Y.; Lee K.K.; Fuller D.H.; Baric R.S.; Kellam P.; Carter L.; Pepper M.; Sheahan T.P.; Veesler D.; King N.P.; Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 2020,183(5),1367-1382.e17","journal-title":"Cell"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"Lee W.S.","year":"2020","unstructured":"Lee W.S.; Wheatley A.K.; Kent S.J.; DeKosky B.J.; Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020,5(10),1185-1191","journal-title":"Nat Microbiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1021\/acs.jmedchem.1c02000","volume":"65","author":"Wang J.","year":"2022","unstructured":"Wang J.; Wen Y.; Zhou S.H.; Zhang H.W.; Peng X.Q.; Zhang R.Y.; Yin X.G.; Qiu H.; Gong R.; Yang G.F.; Guo J.; Self-Adjuvanting Lipoprotein Conjugate \u03b1GalCer-RBD Induces potent immunity against SARS-CoV-2 and its variants of concern. J Med Chem 2022,65(3),2558-2570","journal-title":"J Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"105552","DOI":"10.1016\/j.compbiomed.2022.105552","volume":"146","author":"Nag A.","year":"2022","unstructured":"Nag A.; Banerjee R.; Paul S.; Kundu R.; Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study. Comput Biol Med 2022,146,105552","journal-title":"Comput Biol Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.cell.2022.01.001","volume":"185","author":"Han P.","year":"2022","unstructured":"Han P.; Li L.; Liu S.; Wang Q.; Zhang D.; Xu Z.; Han P.; Li X.; Peng Q.; Su C.; Huang B.; Li D.; Zhang R.; Tian M.; Fu L.; Gao Y.; Zhao X.; Liu K.; Qi J.; Gao G.F.; Wang P.; Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2. Cell 2022,185(4),630-640.e10","journal-title":"Cell"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"103297","DOI":"10.1016\/j.sjbs.2022.103297","volume":"29","author":"Bahadur Gurung A.","year":"2022","unstructured":"Bahadur Gurung A.; Ajmal Ali M.; Elshikh M.S.; Aref I.; Amina M.; Lee J.; An in silico approach unveils the potential of antiviral compounds in preclinical and clinical trials as SARS-CoV-2 omicron inhibitors. Saudi J Biol Sci 2022,29(6),103297","journal-title":"Saudi J Biol Sci"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"103936","DOI":"10.1016\/j.compbiomed.2020.103936","volume":"124","author":"Vardhan S.","year":"2020","unstructured":"Vardhan S.; Sahoo S.K.; In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Comput Biol Med 2020,124,103936","journal-title":"Comput Biol Med"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12906-020-02890-y","volume":"20","author":"Bae J.R.","year":"2020","unstructured":"Bae J.R.; Park W.H.; Suh D.H.; No J.H.; Kim Y.B.; Kim K.; Role of limonin in anticancer effects of Evodia rutaecarpa on ovarian cancer cells. BMC Complement Med Therap 2020,20(1),94","journal-title":"BMC Complement Med Therap"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.3390\/molecules24203679","volume":"24","author":"Fan S.","year":"2019","unstructured":"Fan S.; Zhang C.; Luo T.; Wang J.; Tang Y.; Chen Z.; Yu L.; Limonin: A Review of Its Pharmacology, Toxicity, and Pharmacokinetics. Molecules 2019,24(20),3679","journal-title":"Molecules"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1021\/acs.jafc.0c06775","volume":"69","author":"Yang R.","year":"2021","unstructured":"Yang R.; Yu H.; Chen J.; Zhu J.; Song C.; Zhou L.; Sun Y.; Zhang Q.; Limonin Attenuates LPS-Induced Hepatotoxicity by Inhibiting Pyroptosis via NLRP3\/Gasdermin D Signaling Pathway. J Agric Food Chem 2021,69(3),982-991","journal-title":"J Agric Food Chem"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"105367","DOI":"10.1016\/j.compbiomed.2022.105367","volume":"144","author":"Vardhan S.","year":"2022","unstructured":"Vardhan S.; Sahoo S.K.; Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid. Comput Biol Med 2022,144,105367","journal-title":"Comput Biol Med"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2174\/1570180819666220106110133","volume":"19","author":"Santos Nascimento I.J.","year":"2022","unstructured":"Santos Nascimento I.J.; Silva-J\u00fanior E.F.; Aquino T.M.; Repurposing FDA-approved drugs targeting SARS-CoV2 3CL pro: A Study by applying virtual screening, molecular dynamics, MM-PBSA calculations and covalent docking. Lett Drug Des Discov 2022,19(7),637-653","journal-title":"Lett Drug Des Discov"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"127377","DOI":"10.1016\/j.bmcl.2020.127377","volume":"30","author":"Ullrich S.","year":"2020","unstructured":"Ullrich S.; Nitsche C.; The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett 2020,30(17),127377","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","volume":"371","author":"Qiao J.","year":"2021","unstructured":"Qiao J.; Li Y.-S.; Zeng R.; Liu F.-L.; Luo R.-H.; Huang C.; Wang Y.-F.; Zhang J.; Quan B.; Shen C.; Mao X.; Liu X.; Sun W.; Yang W.; Ni X.; Wang K.; Xu L.; Duan Z.-L.; Zou Q.-C.; Zhang H.-L.; Qu W.; Long Y.-H.-P.; Li M.-H.; Yang R.-C.; Liu X.; You J.; Zhou Y.; Yao R.; Li W.-P.; Liu J.-M.; Chen P.; Liu Y.; Lin G.-F.; Yang X.; Zou J.; Li L.; Hu Y.; Lu G.-W.; Li W.-M.; Wei Y.-Q.; Zheng Y.-T.; Lei J.; Yang S.; SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model. Science 2021,371(6536),1374-1378","journal-title":"Science"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e2101555118","DOI":"10.1073\/pnas.2101555118","volume":"118","author":"Dampalla C.S.","year":"2021","unstructured":"Dampalla C.S.; Zheng J.; Perera K.D.; Wong L.Y.R.; Meyerholz D.K.; Nguyen H.N.; Kashipathy M.M.; Battaile K.P.; Lovell S.; Kim Y.; Perlman S.; Groutas W.C.; Chang K.O.; Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc Natl Acad Sci USA 2021,118(29),e2101555118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=114","first-page":"6575","volume":"374","author":"Owen D.R.","year":"2021","unstructured":"Owen D.R.; Allerton C.M.N.; Anderson A.S.; Aschenbrenner L.; Avery M.; Berritt S.; Boras B.; Cardin R.D.; Carlo A.; Coffman K.J.; Dantonio A.; Di L.; Eng H.; Ferre R.; Gajiwala K.S.; Gibson S.A.; Greasley S.E.; Hurst B.L.; Kadar E.P.; Kalgutkar A.S.; Lee J.C.; Lee J.; Liu W.; Mason S.W.; Noell S.; Novak J.J.; Obach R.S.; Ogilvie K.; Patel N.C.; Pettersson M.; Rai D.K.; Reese M.R.; Sammons M.F.; Sathish J.G.; Singh R.S.P.; Steppan C.M.; Stewart A.E.; Tuttle J.B.; Updyke L.; Verhoest P.R.; Wei L.; Yang Q.; Zhu Y.; An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19. Science 2021,374(6575),6575-1593","journal-title":"Science"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"101972","DOI":"10.1016\/j.jbc.2022.101972","volume":"298","author":"Greasley S.E.","year":"2022","unstructured":"Greasley S.E.; Noell S.; Plotnikova O.; Ferre R.; Liu W.; Bolanos B.; Fennell K.; Nicki J.; Craig T.; Zhu Y.; Stewart A.E.; Steppan C.M.; Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem 2022,298(6),101972","journal-title":"J Biol Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","volume":"198","author":"Vangeel L.","year":"2022","unstructured":"Vangeel L.; Chiu W.; De Jonghe S.; Maes P.; Slechten B.; Raymenants J.; Andr\u00e9 E.; Leyssen P.; Neyts J.; Jochmans D.; Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res 2022,198,105252","journal-title":"Antiviral Res"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","volume":"32","author":"Li P.","year":"2022","unstructured":"Li P.; Wang Y.; Lavrijsen M.; Lamers M.M.; de Vries A.C.; Rottier R.J.; Bruno M.J.; Peppelenbosch M.P.; Haagmans B.L.; Pan Q.; SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res 2022,32(3),322-324","journal-title":"Cell Res"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1021\/np50124a002","volume":"58","author":"Paulo A.","year":"1995","unstructured":"Paulo A.; Gomes E.T.; Houghton P.J.; New Alkaloids from Cryptolepis sanguinolenta. J Nat Prod 1995,58(10),1485-1491","journal-title":"J Nat Prod"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/0040-4039(96)00112-8","volume":"37","author":"Cimanga K.","year":"1996","unstructured":"Cimanga K.; De Bruyne T.; Pieters L.; Claeys M.; Vlietinck A.; New alkaloids from Cryptolepis sanguinolenta. Tetrahedron Lett 1996,37(10),1703-1706","journal-title":"Tetrahedron Lett"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ardp.19883210811","volume":"321","author":"Ambros R.","year":"1988","unstructured":"Ambros R.; Angerer S.V.; Wiegrebe W.; Synthesis and antitumor activity of methoxy-indolo[2,1-a]isoquinolines. Arch Pharm 1988,321(8),481-486","journal-title":"Arch Pharm"},{"key":"ref=121","first-page":"251","volume":"14","author":"Saundane A.R.","year":"1998","unstructured":"Saundane A.R.; Ranganath S.H.; Prayagraj G.; Rudresh K.; Satyanarayana N.D.; Synthesis and Pharmacological Studies of Some New 11H- Indolo[3,2-C] Isoquinolin-5-Ylthio)Acetyl Thiosemicarbazide Andits Derivatives. Orient J Chem 1998,14,251-254","journal-title":"Orient J Chem"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"133153","DOI":"10.1016\/j.molstruc.2022.133153","volume":"1264","author":"Verma V.A.","year":"2022","unstructured":"Verma V.A.; Saundane A.R.; Shamrao R.; Meti R.S.; Shinde V.M.; Novel indolo [3,2-c]isoquinoline-5-one-6-yl [1,2,4]triazolo [3,4-b] [1,3,4]thiadiazole analogues: Design, synthesis, anticancer activity, docking with SARS-CoV-2 Omicron protease and MESP\/TD-DFT approaches. J Mol Struct 2022,1264,133153","journal-title":"J Mol Struct"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Unoh Y.","year":"2022","unstructured":"Unoh Y.; Uehara S.; Nakahara K.; Nobori H.; Yamatsu Y.; Yamamoto S.; Maruyama Y.; Taoda Y.; Kasamatsu K.; Suto T.; Kouki K.; Nakahashi A.; Kawashima S.; Sanaki T.; Toba S.; Uemura K.; Mizutare T.; Ando S.; Sasaki M.; Orba Y.; Sawa H.; Sato A.; Sato T.; Kato T.; Tachibana Y.; Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 2022,65(9),6499-6512","journal-title":"J Med Chem"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00705-012-1404-x","volume":"157","author":"Ahn D.G.","year":"2012","unstructured":"Ahn D.G.; Choi J.K.; Taylor D.R.; Oh J.W.; Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Arch Virol 2012,157(11),2095-2104","journal-title":"Arch Virol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.csbj.2022.02.001","volume":"20","author":"Uengwetwanit T.","year":"2022","unstructured":"Uengwetwanit T.; Chutiwitoonchai N.; Wichapong K.; Karoonuthaisiri N.; Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity. Comput Struct Biotechnol J 2022,20,882-890","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fgene.2017.00125","volume":"8","author":"de Farias S.T.","year":"2017","unstructured":"de Farias S.T.; dos Santos Junior, A.P.; R\u00eago T.G.; Jos\u00e9 M.V.; Origin and Evolution of RNA-Dependent RNA Polymerase. Front Genet 2017,8,125","journal-title":"Front Genet"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","volume":"584","author":"Hillen H.S.","year":"2020","unstructured":"Hillen H.S.; Kokic G.; Farnung L.; Dienemann C.; Tegunov D.; Cramer P.; Structure of replicating SARS-CoV-2 polymerase. Nature 2020,584(7819),154-156","journal-title":"Nature"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"e02428","DOI":"10.1128\/AAC.02428-20","volume":"65","author":"Painter W.P.","year":"2021","unstructured":"Painter W.P.; Holman W.; Bush J.A.; Almazedi F.; Malik H.; Eraut N.C.J.E.; Morin M.J.; Szewczyk L.J.; Painter G.R.; Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 2021,65(5),e02428-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"e01348","DOI":"10.1128\/JVI.01348-19","volume":"93","author":"Agostini M.L.","year":"2019","unstructured":"Agostini M.L.; Pruijssers A.J.; Chappell J.D.; Gribble J.; Lu X.; Andres E.L.; Bluemling G.R.; Lockwood M.A.; Sheahan T.P.; Sims A.C.; Natchus M.G.; Saindane M.; Kolykhalov A.A.; Painter G.R.; Baric R.S.; Denison M.R.; Small-Molecule Antiviral \u03b2- D-N4 -Hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol 2019,93(24),e01348-e19","journal-title":"J Virol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"104597","DOI":"10.1016\/j.antiviral.2019.104597","volume":"171","author":"Painter G.R.","year":"2019","unstructured":"Painter G.R.; Bowen R.A.; Bluemling G.R.; DeBergh J.; Edpuganti V.; Gruddanti P.R.; Guthrie D.B.; Hager M.; Kuiper D.L.; Lockwood M.A.; Mitchell D.G.; Natchus M.G.; Sticher Z.M.; Kolykhalov A.A.; The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antiviral Res 2019,171,104597","journal-title":"Antiviral Res"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jsps.2022.03.002","volume":"30","author":"Kamal L.","year":"2022","unstructured":"Kamal L.; Ramadan A.; Farraj S.; Bahig L.; Ezzat S.; The pill of recovery; Molnupiravir for treatment of COVID-19 patients; A systematic review. Saudi Pharm J 2022,30(5),508-518","journal-title":"Saudi Pharm J"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"e160108","DOI":"10.1172\/jci.insight.160108","volume":"7","author":"Rosenke K.","year":"2022","unstructured":"Rosenke K.; Okumura A.; Lewis M.C.; Feldmann F.; Meade-White K.; Bohler W.F.; Griffin A.; Rosenke R.; Shaia C.; Jarvis M.A.; Feldmann H.; Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model. JCI Insight 2022,7(13),e160108","journal-title":"JCI Insight"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"Beigel J.H.","year":"2020","unstructured":"Beigel J.H.; Tomashek K.M.; Dodd L.E.; Mehta A.K.; Zingman B.S.; Kalil A.C.; Hohmann E.; Chu H.Y.; Luetkemeyer A.; Kline S.; Lopez de Castilla D.; Finberg R.W.; Dierberg K.; Tapson V.; Hsieh L.; Patterson T.F.; Paredes R.; Sweeney D.A.; Short W.R.; Touloumi G.; Lye D.C.; Ohmagari N.; Oh M.; Ruiz-Palacios G.M.; Benfield T.; F\u00e4tkenheuer G.; Kortepeter M.G.; Atmar R.L.; Creech C.B.; Lundgren J.; Babiker A.G.; Pett S.; Neaton J.D.; Burgess T.H.; Bonnett T.; Green M.; Makowski M.; Osinusi A.; Nayak S.; Lane H.C.; Remdesivir for the treatment of Covid-19 \u2014 Final report. N Engl J Med 2020,383(19),1813-1826","journal-title":"N Engl J Med"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","volume":"386","author":"Gottlieb R.L.","year":"2022","unstructured":"Gottlieb R.L.; Vaca C.E.; Paredes R.; Mera J.; Webb B.J.; Perez G.; Oguchi G.; Ryan P.; Nielsen B.U.; Brown M.; Hidalgo A.; Sachdeva Y.; Mittal S.; Osiyemi O.; Skarbinski J.; Juneja K.; Hyland R.H.; Osinusi A.; Chen S.; Camus G.; Abdelghany M.; Davies S.; Behenna-Renton N.; Duff F.; Marty F.M.; Katz M.J.; Ginde A.A.; Brown S.M.; Schiffer J.T.; Hill J.A.; Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022,386(4),305-315","journal-title":"N Engl J Med"},{"author":"Gomaa A.","key":"ref=135","unstructured":"Gomaa A.; Complementary Intervention for COVID-19. Available From:  [Accessed on Jul 11, 2022]."},{"author":"Aarogyam U.","key":"ref=136","unstructured":"Aarogyam U.; a pilot study on efficacy and safety of ayurveda combination in patients with mild-to-moderate COVID-19. Available From:  [Accessed on Jul 11, 2022]."},{"author":"Aarogyam U.","key":"ref=137","unstructured":"Aarogyam U.; Feasibility of ayurveda in patients with mild-tomoderate COVID-19: A community-based participatory research. Available From:  [Accessed on Jul 11, 2022]."},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jiph.2022.05.002","volume":"15","author":"Roshni J.","year":"2022","unstructured":"Roshni J.; Vaishali R.; Ganesh K.S.; Dharani N.; Alzahrani K.J.; Banjer H.J.; Alghamdi A.H.; Theyab A.; Ahmed S.S.S.J.; Patil S.; Multi-target potential of Indian phytochemicals against SARS-CoV-2: A docking, molecular dynamics and MM-GBSA approach extended to Omicron B.1.1.529. J Infect Public Health 2022,15(6),662-669","journal-title":"J Infect Public Health"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230411095417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215649\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026623666230411095417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:33:49Z","timestamp":1695123229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215649\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":138,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,8,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026623666230411095417","relation":{},"ISSN":["1568-0266"],"issn-type":[{"type":"print","value":"1568-0266"}],"subject":[],"published":{"date-parts":[[2023,8,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}